Bile Duct Cancer Market – By Type (Extrahepatic Bile Duct Cancer, Intrahepatic Bile Duct Cancer), By Treatment (Surgery, Chemotherapy, Radiation, Targeted, & Immunotherapy), By End-use (Hospitals, Oncology Centers, ASCs) & Forecast, 2024 – 2032

Bile Duct Cancer Market Size

Bile Duct Cancer Market size was valued at USD 3.6 billion in 2023 and is expected to expand at a CAGR of 8.5% between 2024 and 2032. One of the major growth drivers is the increasing incidence of bile duct cancer globally, which has led to a greater demand for effective treatment options. Additionally, advancements in medical technology and increased awareness among healthcare professionals and patients have contributed to the market's growth.
 

Furthermore, the rise in research and development activities focusing on innovative therapies and targeted treatments for bile duct cancer has propelled market expansion. For instance, in 2021, the U.S. FDA granted accelerated approval to the targeted therapeutic infigratinib (Truseltiq) for certain adults with previously treated advanced cholangiocarcinoma. Thus, with ongoing efforts to improve early detection and development of more personalized treatment approaches.
 

Bile duct cancer, also known as cholangiocarcinoma, is a rare but aggressive type of cancer that forms in the bile ducts, which are thin tubes that connect the liver and the gallbladder to the small intestine. Bile duct cancer can occur in any part of the bile duct system, including the intrahepatic (inside the liver) and extrahepatic (outside the liver) bile ducts.
 

Bile Duct Cancer Market Trends

• The rising incidence of bile duct cancer is a significant driver of the bile duct cancer industry globally.
   
• For instance, as per the National Cancer Institute, the rate of new cases of liver and intrahepatic bile duct cancer in the U.S. is 9.3 per 100,000 men and women per year, with an estimated 41,210 new cases in 2023.
   
• This increase in incidence is attributed to various factors, including aging populations, changing lifestyles, environmental factors, and a rise in risk factors such as chronic liver diseases, bile duct stones, and infections with liver flukes.
   
• Thus, as the incidence of bile duct cancer continues to rise, there is a growing need for effective therapeutic options, driving the growth of the market.
   
• Additionally, development of innovative liver cancer diagnostics is aiding in early detection, further enhances the market growth.
   

Bile Duct Cancer Market Analysis

Based on type, the market is segmented into extrahepatic bile duct cancer (eCCA) and intrahepatic bile duct cancer (iCCA). The intrahepatic bile duct cancer (eCCA) segment dominated around USD 2.4 billion revenue in 2023.
 

• iCCA is a relatively common type of bile duct cancer, comprising the majority of cases, and its incidence has been increasing globally. iCCA accounts for around 5%–20% of cases of primary liver cancer.
   
• This rise in prevalence has led to a greater focus on developing advanced treatment options specifically tailored for iCCA.
   
• Additionally, the lack of effective screening methods for early detection and the often-advanced stage at diagnosis contribute to the high demand for innovative therapies in this segment.
   
• As a result, pharmaceutical companies and research institutions are actively investing in the development of novel drugs and treatment modalities targeting iCCA, thereby driving the segment's growth.

Based on treatment, the bile duct cancer market is segmented into surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. The surgery segment accounted for 36.3% of the market share in 2023.
 

• Surgical interventions, such as the removal of the tumor or bypass procedures are preferred options for localized bile duct cancers.
   
• Additionally, advent of advanced surgical techniques such as minimally invasive approaches that enable more precise and effective procedures, have further increased adoption rates.
   
• Moreover, the limited efficacy of alternative treatment modalities, particularly in advanced stages of the disease, makes surgery a primary option for achieving tumor control and improving survival rates, further enhancing the segmental growth.
   

Based on treatment provider, the bile duct cancer market is classified into hospitals, oncology centers & specialty clinics, and ambulatory surgical centers. The hospitals segment is poised to reach USD 3.5 billion by 2032.
 

• Hospitals are well equipped with advanced diagnostic technologies such as CT scans, MRIs, and endoscopic retrograde cholangiopancreatography (ERCP), which are essential for accurate diagnosis and staging of bile duct cancer.
   
• Additionally, hospitals have multidisciplinary teams of oncologists, surgeons, radiologists, and other specialists who collaborate to develop personalized treatment plans for patients, including surgery, chemotherapy, and radiation therapy.
   
• Furthermore, hospitals serve as the primary healthcare settings with a higher volume of patients seeking specialized care.

North America bile duct cancer market held over 37.8% of the revenue share in 2023 and is expected to cross USD 2.7 billion by 2032.
 

• The region benefits from a well-established healthcare infrastructure, high adoption of advanced medical technologies, and a growing prevalence of bile duct cancer cases.
   
• For instance, as per the Dana-Farber Cancer Institute, approximately 10,000 Americans are diagnosed with cancer of the biliary tract each year.
   
• Additionally, increased awareness about early diagnosis and treatment options, along with favorable government initiatives and reimbursement policies, contribute to the region's dominance in this market.
   
• Furthermore, the presence of key market players focusing on research and development activities to introduce novel therapeutics and treatment approaches further solidifies North America's position as a leader in the market.
   

Bile Duct Cancer Market Share

The bile duct cancer industry is characterized by the presence of established players offering a range of treatments and therapeutic approaches for bile duct cancer. Key players compete on factors such as product efficacy, safety profile, pricing, distribution networks, regulatory landscape, and brand reputation. Continuous focus on innovation, strategic partnerships, and mergers and acquisitions are common strategies employed to gain a competitive edge in this dynamic and evolving market.
 

Bile Duct Cancer Market Companies

Prominent players operating in the bile duct cancer industry are as mentioned below:

• AbbVie Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Fresenius SE & Co. KGaA
• Genentech, Inc.
• GlaxoSmithKline plc.
• Incyte Corporation
• Merck & Co., Inc.
• Pfizer Inc.
• QED Therapeutics
   

Bile Duct Cancer Industry News

• In November 2023, Merck & Co., Inc. received the U.S. FDA approval for KEYTRUDA, anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). This approval marked the sixth indication for KEYTRUDA in gastrointestinal cancer, and helped the company expand its sales.
   
• In April 2020, Incyte received the U.S. FDA approval for Pemazyre (pemigatinib), a kinase inhibitor, as first targeted treatment for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma. Pemazyre was the first targeted treatment approved for this specific patient population, giving the company a competitive edge in the market.
   

The bile duct cancer market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Extrahepatic bile duct cancer (eCCA)
• Intrahepatic bile duct cancer (iCCA)

Market, By Treatment

• Surgery
• Chemotherapy
• Radiation therapy
• Targeted therapy
• Immunotherapy

Market, By Treatment Provider

• Hospitals
• Oncology centers & specialty clinics
• Ambulatory surgical centers (ASCs)

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa